Trial results

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

NCT05965908 on ClinicalTrials.gov · last registry update 2026-08-25

A small phase 3 — 183 participants, against a typical 424. The sponsor logged completion for 30 November 2025. Primary outcome, as filed: Insulin Resistance (HOMA-IR). liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P3

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

Beni-Suef University

Sponsor type

Other

Enrollment

183

Started

2024-08-01

Primary completion

2025-11-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Insulin Resistance (HOMA-IR)

Conditions studied

Polycystic Ovary

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.